New hope for head and neck cancer patients who Can't take standard chemo
NCT ID NCT07441681
First seen Mar 10, 2026 · Last updated Apr 24, 2026 · Updated 2 times
Summary
This study tests two different treatments for people with advanced head and neck cancer who cannot receive the standard drug cisplatin. One group gets a targeted therapy called cetuximab plus radiation, while the other gets a different chemotherapy combination (carboplatin and paclitaxel) plus radiation. The goal is to see which approach works better at stopping the cancer from growing. About 454 adults with certain types of head and neck cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE I HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.